Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

BACKGROUND: Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients with solid tumors usi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4596876/
https://ncbi.nlm.nih.gov/pubmed/26445503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0139679
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars